Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.75 |
| ▸ | MMP2 | P08253 | 1/20 | 0.75 |
| ▸ | MMP9 | P14780 | 1/20 | 0.75 |
| ▸ | MMP8 | P22894 | 1/20 | 0.75 |
| ▸ | MMP13 | P45452 | 1/20 | 0.75 |
| ▸ | CRHBP | P24387 | 1/20 | 0.68 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | HTT | P42858 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2153255 | 0.88 | MEN1 (0.66) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL2153021 | 0.82 | ALDH1A1 (0.70) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL2153304 | 0.82 | ALDH1A1 (0.74) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL12839889 | 0.81 | ALDH1A1 (0.68) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL2153243 | 0.79 | ALDH1A1 (1.00) | ALDH1A1HTTMEN1KMT2ALMNA | |
| SCHEMBL11059936 | 0.78 | GAA (0.72) | ALDH1A1HTTMEN1KMT2AL3MBTL1 | |
| 4-Nitrobenzoic Acid SCHEMBL31121231 | 0.75 | CRHBP (0.70) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL11615300 | 0.75 | RAB9A (0.74) | MMP13MEN1KMT2ALMNACYP2C9 | |
| SCHEMBL27815181 | 0.74 | MAPT (0.67) | CRHBPCRHR2ALDH1A1MEN1KMT2A | |
| SCHEMBL11143290 | 0.74 | ALDH1A1 (0.69) | MMP1MMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962244-B2 | Compounds for modulating RNA binding proteins and uses therefor | UNIVERSITY OF MASSACHUSETTS (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962244-B2 | Compounds for modulating RNA binding proteins and uses therefor | UNIVERSITY OF MASSACHUSETTS (US) | 2015-02-24 | — | — | US | disclosed |
| US-20130217685-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217685-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-22 | — | — | US | disclosed |
| US-8377639-B2 | Compounds for modulating RNA binding proteins and uses therefor | UNIVERSITY OF MASSACHUSETTS (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377639-B2 | Compounds for modulating RNA binding proteins and uses therefor | UNIVERSITY OF MASSACHUSETTS (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | Zacharon Pharmaceutical, Inc. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011082175-A2 | GLYCOSAMINOGLYCAN INHIBITORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-17 | — | — | US | disclosed |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-17 | — | — | US | disclosed |
| WO-2010151797-A2 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | UNIVERSITY OF MASSACHUSETTS (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217685-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | TIA1, ZFP3, RBM3 | MMP1 3948/4885MMP2 4802/4885MMP9 4739/4885 |
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | CSGALNACT1, FUT5, ST3GAL3 | MMP1 233/4885MMP2 180/4885MMP9 215/4885 |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | TIA1, ZFP3, RBM3 | MMP1 3948/4885MMP2 4802/4885MMP9 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.